![Simon Jones PhD, BSc (Hons) FLSW MAE FRSB](https://profiles-cardiff.imgix.net/attachments/4242?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Simon Jones
PhD, BSc (Hons) FLSW MAE FRSB
Co-Director, Systems Immunity Research Institute
- Media commentator
Overview
Simon Jones has made important contributions to the field of cytokine biology with translational impact on the clinic. His research elicited fundamental mechanisms whereby cytokines promote immune-mediated diseases. These include discoveries offering a persuasive explanation of rheumatoid arthritis heterogeneity upon exposure to biological drugs. He led the first studies describing the importance of interleukin-6 trans-signalling in inflammation, identifying the physiological regulation of this signalling pathway, and pioneering the inhibition of interleukin-6 trans-signalling by olamkicept. His work is cited highly in contemporary literature and includes publications in journals of repute (e.g., Nature Immunology, Immunity, and Journal of Experimental Medicine).
In recognition of this leadership, Jones was elected Fellow of the Learned Society of Wales and Member of the Academia Europaea. He has generated over £25M in grant awards, including funding from UKRI, charities (e.g., Versus Arthritis, Wellcome Trust), and industry. He was Dean of Research for the School of Medicine at Cardiff (2017-2021) and was recently appointed Co-Director of the Systems Immunity Research Institute, where he leads Multimorbidity Research.
Jones is committed to mentorship. His post-doctoral researchers have transitioned to tenured appointments (1x Professor, 1x Assistant Professor, 2x Senior Lecturers, 2x Lecturer). Others secured independent fellowships (x4) or positions in industry (x3), medical writing (x2) and university administration (x1). His former PhD students remain in academic research.
Jones actively supports the scientific community, particularly advancing understanding between fundamental and clinical researchers. He serves on grant‑awarding panels and editorial boards and contributed to the launch of government and charity-led initiatives. Jones advises the pharmaceutical sector on cytokine-targeting therapies and communicates educational programmes for healthcare professionals on this topic. Recently, he chaired the organising committee for the 2021 International Cytokine & Interferon Society meeting.
Publication
2024
- Odd, D., Sabir, H., Jones, S. A., Gale, C. and Chakkarapani, E. 2024. Risk factors for infection and outcomes in infants with neonatal encephalopathy: a cohort study. Pediatric Research 96, pp. 785-791. (10.1038/s41390-024-03157-9)
2023
- Millrine, D. et al. 2023. Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements. The Journal of Immunology 211(2), pp. 274-286. (10.4049/jimmunol.2300114)
- Clement, M. et al. 2023. Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1. eLife 12, article number: e79165. (10.7554/eLife.79165)
- Millrine, D., Rice, C. M., Fernandez, J. U. and Jones, S. A. 2023. Tracking the host response to infection in peritoneal models of acute resolving inflammation. In: Jenkins, B. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York: Springer, pp. 81-95., (10.1007/978-1-0716-3331-1_7)
- Karhunen, V. et al. 2023. The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. BMJ Medicine 2(1), article number: e000157. (10.1136/bmjmed-2022-000157)
2022
- Millrine, D., Jenkins, R. H., Hughes, S. T. O. and Jones, S. A. 2022. Making sense of IL-6 signalling cues in pathophysiology. FEBS Letters 596(5), pp. 567-588. (10.1002/1873-3468.14201)
- Misheva, M. et al. 2022. Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation. Nature Communications 13(1), article number: 139. (10.1038/s41467-021-27766-8)
2021
- Jenkins, R. H., Hughes, S. T., Cardus Figueras, A. and Jones, S. A. 2021. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 148, article number: 155684. (10.1016/j.cyto.2021.155684)
- Heise, D. et al. 2021. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Science Signaling 14(696), article number: eabc3480. (10.1126/scisignal.abc3480)
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
- Jones, S. A. and Hunter, C. A. 2021. Is IL-6 a key cytokine target for therapy in COVID-19?. Nature Reviews Immunology 21(6), pp. 337–339. (10.1038/s41577-021-00553-8)
2020
- Jones, S. A., Bryant, C., Lloyd, C. M., McInnes, I. and O'Neill, L. 2020. A vision for cytokine biology with 20/20 clarity. Function 2(1), article number: zqaa042. (10.1093/function/zqaa042)
- Ponsford, M. J. et al. 2020. Cardiometabolic traits, sepsis, and severe COVID-19. Circulation 142(18), pp. 1791–1793. (10.1161/CIRCULATIONAHA.120.050753)
- Lucchesi, D. et al. 2020. Impaired IL‐27 mediated control of CD4+ T cell function impacts on ectopic lymphoid structure formation in patients with Sjögren's Syndrome. Arthritis and Rheumatology 72(9), pp. 1559-1570., article number: Volume72, Issue9 September 2020 Pages 1559-1570. (10.1002/art.41289)
- Harbour, S. N. et al. 2020. Th17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Science Immunology 5(49), article number: eaaw2262. (10.1126/sciimmunol.aaw2262)
- O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1(1), article number: zqaa002. (10.1093/function/zqaa002)
2019
- Jones, H. J., Hubbard, L., Mitchell, R. E., Jones, S. A., Williams, N. M., Zammit, S. and Hall, J. 2019. Association of genetic risk for rheumatoid arthritis with cognitive and psychiatric phenotypes across childhood and adolescence. JAMA Network Open 2(6), pp. -., article number: e196118. (10.1001/jamanetworkopen.2019.6118)
- Twohig, J. P. et al. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20, pp. 458-470. (10.1038/s41590-019-0350-0)
- Jones, S. A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E. H. and McInnes, I. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
- Takeuchi, T., Smolen, J. S., Choy, E., Aletaha, D., McInnes, I. and Jones, S. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
- Smolen, J. S., Aletaha, D., Choy, E., Jones, S., Takeuchi, T. and McInnes, I. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
- Choy, E., Jones, S., Aletaha, D., Takeuchi, T., McInnes, I. and Smolen, J. S. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
2018
- Rivellese, F. et al. 2018. Mast cells in early rheumatoid arthritis associate with disease severity and support B-cell autoantibody production. Annals of the Rheumatic Diseases 77(12), pp. 1773-1781. (10.1136/annrheumdis-2018-213418)
- Jones, S. A. and Jenkins, B. J. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Reviews Immunology 18, pp. 773-789. (10.1038/s41577-018-0066-7)
- Jones, G., Hill, D., Cardus Figueras, A. and Jones, S. 2018. IL-27 - a double agent in the IL-6 family. Clinical and Experimental Immunology 193(1), pp. 37-46. (10.1111/cei.13116)
- Fernandez, J. U., Millrine, D. and Jones, S. 2018. Tracking competent host defence to chronic inflammation: An In Vivo model of peritonitis. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 1725. Methods in Molecular Biology New York, NY: Springer, pp. 65-75., (10.1007/978-1-4939-7568-6_6)
2017
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10(507), article number: eaan2787. (10.1126/scisignal.aan2787)
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Catar, R. et al. 2017. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. Journal of the American Society of Nephrology 28(4), pp. 1188-1199. (10.1681/ASN.2015101169)
- Dutzan, N. et al. 2017. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. Immunity 46(1), pp. 133-147. (10.1016/j.immuni.2016.12.010)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2(1) (10.12688/wellcomeopenres.10308.1)
2016
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
- Jones, G., Hill, D. and Jones, S. 2016. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Frontiers in Immunology 7, pp. 1-13., article number: 401. (10.3389/fimmu.2016.00401)
- Liao, C. et al. 2016. IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation. European Journal of Immunology 46(9), pp. 2222-2232. (10.1002/eji.201646528)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Liu, X., Jones, G. W., Choy, E. H. and Jones, S. A. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
- Jones, G. W. and Jones, S. A. 2016. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147(2), pp. 141-151. (10.1111/imm.12554)
2015
- Lacroix, M. et al. 2015. Novel insights into IL-6 cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. Journal of Biological Chemistry 290, pp. 26943-26953. (10.1074/jbc.M115.682138)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Beyer, C. et al. 2015. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases 74(6), pp. 1317-1324. (10.1136/annrheumdis-2013-204401)
- Hunter, C. A. and Jones, S. A. 2015. IL-6 as a keystone cytokine in health and disease. Nature Immunology 16(5), pp. 448-457. (10.1038/ni.3153)
2014
- Rosser, E. C. et al. 2014. Regulatory B cells are induced by gut microbiota- driven interleukin-1β and interleukin-6 production. Nature Medicine 20, pp. 1334-1339. (10.1038/nm.3680)
- Garbers, C. et al. 2014. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochimica et Biophysica Acta - Molecular Basis of Disease 1842(9), pp. 1485-1494. (10.1016/j.bbadis.2014.05.018)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Pitzalis, C., Jones, G. W., Bombardieri, M. and Jones, S. A. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology 14(7), pp. 447-462. (10.1038/nri3700)
- Rosas, M. et al. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 344(6184), pp. 645-648. (10.1126/science.1251414)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
2013
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Orr, S. J. et al. 2013. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. PLoS Pathogens 9(5), article number: e1003357. (10.1371/journal.ppat.1003357)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
- Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
- Chakraborty, M., McGreal, E. P., Davies, P. L., Nowell, M. A., Jones, S. A. and Kotecha, S. 2013. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. Neonatology 104(3), pp. 161-167. (10.1159/000351015)
2012
- McDonald, J. U., Rosas, M., Brown, G. D., Jones, S. A. and Taylor, P. R. 2012. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS ONE 7(9), article number: e45781. (10.1371/journal.pone.0045781)
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- O'Connor, R. A., Floess, S., Huehn, J., Jones, S. A. and Anderton, S. M. 2012. Foxp3+Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production. European Journal of Immunology 42(5), pp. 1174-1179. (10.1002/eji.201142216)
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
2011
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
- McDonald, J. U. et al. 2011. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. The FASEB Journal 25(6), pp. 1972-1982. (10.1096/fj.10-178517)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Rosas, M. et al. 2011. Hoxb8 conditionally immortalised macrophage lines model inflammatory monocytic cells with important similarity to dendritic cells. European Journal of Immunology 41(2), pp. 356-365. (10.1002/eji.201040962)
- Liddiard, K., Rosas, M., Davies, L. C., Jones, S. A. and Taylor, P. R. 2011. Macrophage heterogeneity and acute inflammation. European Journal of Immunology 41(9), pp. 2503-2508. (10.1002/eji.201141743)
- Davies, L. C., Rosas, M., Smith, P. J., Fraser, D. J., Jones, S. A. and Taylor, P. R. 2011. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. European Journal of Immunology 41(8), pp. 2155-2164. (10.1002/eji.201141817)
- Kennedy, C. L. et al. 2011. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. The Journal of Pathology 225(2), pp. 255-264. (10.1002/path.2933)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Jones, S. A., Scheller, J. and Rose-John, S. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121(9), pp. 3375-3383. (10.1172/JCI57158)
- McGreal, E. P., Chakraborty, M., Winter, V. T., Jones, S. A., Coalson, J. J. and Kotecha, S. 2011. Dynamic expression of IL-6 trans-signalling molecules in the lungs of preterm baboons undergoing mechanical ventilation. Neonatology 100(2), pp. 130-138. (10.1159/000322148)
2010
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Leggate, M., Nowell, M. A., Jones, S. A. and Nimmo, M. N. 2010. The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress and Chaperones 15(6), pp. 827-833. (10.1007/s12192-010-0192-z)
- McGreal, E. P. et al. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease 1802(7-8), pp. 649-658. (10.1016/j.bbadis.2010.04.005)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
2009
- Cash, H. et al. 2009. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. The Journal of Rheumatology 37(1), pp. 60-70. (10.3899/jrheum.090194)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
2008
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Longhi, M. P. et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Dioszeghy, V. et al. 2008. 12/15-lipoxygenase regulates the inflammatory response to bacterial products in vivo. The Journal of Immunology 181(9), pp. 6514-6524.
2007
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
2006
- Dimitrov, S. et al. 2006. Sleep enhances IL-6 trans-signaling in humans. The FASEB Journal 20(12), pp. 2174-2176. (10.1096/fj.06-5754fje)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Peake, N. J. et al. 2006. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45(12), pp. 1485-1489. (10.1093/rheumatology/kel154)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
2005
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
2004
- McLoughlin, R. M. et al. 2004. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. The Journal of Immunology 172, pp. 5676-83.
2003
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
2001
- Robson, R. L., McLoughlin, R. M., Witowski, J., Loetscher, P., Wilkinson, T. S., Jones, S. A. and Topley, N. 2001. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo. The Journal of Immunology 167(2), pp. 1028-1038.
- Hurst, S. M. et al. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6), pp. 705-714. (10.1016/S1074-7613(01)00151-0)
Adrannau llyfrau
- Millrine, D., Rice, C. M., Fernandez, J. U. and Jones, S. A. 2023. Tracking the host response to infection in peritoneal models of acute resolving inflammation. In: Jenkins, B. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York: Springer, pp. 81-95., (10.1007/978-1-0716-3331-1_7)
- Fernandez, J. U., Millrine, D. and Jones, S. 2018. Tracking competent host defence to chronic inflammation: An In Vivo model of peritonitis. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 1725. Methods in Molecular Biology New York, NY: Springer, pp. 65-75., (10.1007/978-1-4939-7568-6_6)
Erthyglau
- Odd, D., Sabir, H., Jones, S. A., Gale, C. and Chakkarapani, E. 2024. Risk factors for infection and outcomes in infants with neonatal encephalopathy: a cohort study. Pediatric Research 96, pp. 785-791. (10.1038/s41390-024-03157-9)
- Millrine, D. et al. 2023. Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements. The Journal of Immunology 211(2), pp. 274-286. (10.4049/jimmunol.2300114)
- Clement, M. et al. 2023. Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1. eLife 12, article number: e79165. (10.7554/eLife.79165)
- Karhunen, V. et al. 2023. The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. BMJ Medicine 2(1), article number: e000157. (10.1136/bmjmed-2022-000157)
- Millrine, D., Jenkins, R. H., Hughes, S. T. O. and Jones, S. A. 2022. Making sense of IL-6 signalling cues in pathophysiology. FEBS Letters 596(5), pp. 567-588. (10.1002/1873-3468.14201)
- Misheva, M. et al. 2022. Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation. Nature Communications 13(1), article number: 139. (10.1038/s41467-021-27766-8)
- Jenkins, R. H., Hughes, S. T., Cardus Figueras, A. and Jones, S. A. 2021. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 148, article number: 155684. (10.1016/j.cyto.2021.155684)
- Heise, D. et al. 2021. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Science Signaling 14(696), article number: eabc3480. (10.1126/scisignal.abc3480)
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
- Jones, S. A. and Hunter, C. A. 2021. Is IL-6 a key cytokine target for therapy in COVID-19?. Nature Reviews Immunology 21(6), pp. 337–339. (10.1038/s41577-021-00553-8)
- Jones, S. A., Bryant, C., Lloyd, C. M., McInnes, I. and O'Neill, L. 2020. A vision for cytokine biology with 20/20 clarity. Function 2(1), article number: zqaa042. (10.1093/function/zqaa042)
- Ponsford, M. J. et al. 2020. Cardiometabolic traits, sepsis, and severe COVID-19. Circulation 142(18), pp. 1791–1793. (10.1161/CIRCULATIONAHA.120.050753)
- Lucchesi, D. et al. 2020. Impaired IL‐27 mediated control of CD4+ T cell function impacts on ectopic lymphoid structure formation in patients with Sjögren's Syndrome. Arthritis and Rheumatology 72(9), pp. 1559-1570., article number: Volume72, Issue9 September 2020 Pages 1559-1570. (10.1002/art.41289)
- Harbour, S. N. et al. 2020. Th17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Science Immunology 5(49), article number: eaaw2262. (10.1126/sciimmunol.aaw2262)
- O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1(1), article number: zqaa002. (10.1093/function/zqaa002)
- Jones, H. J., Hubbard, L., Mitchell, R. E., Jones, S. A., Williams, N. M., Zammit, S. and Hall, J. 2019. Association of genetic risk for rheumatoid arthritis with cognitive and psychiatric phenotypes across childhood and adolescence. JAMA Network Open 2(6), pp. -., article number: e196118. (10.1001/jamanetworkopen.2019.6118)
- Twohig, J. P. et al. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20, pp. 458-470. (10.1038/s41590-019-0350-0)
- Jones, S. A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E. H. and McInnes, I. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
- Takeuchi, T., Smolen, J. S., Choy, E., Aletaha, D., McInnes, I. and Jones, S. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
- Smolen, J. S., Aletaha, D., Choy, E., Jones, S., Takeuchi, T. and McInnes, I. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
- Choy, E., Jones, S., Aletaha, D., Takeuchi, T., McInnes, I. and Smolen, J. S. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
- Rivellese, F. et al. 2018. Mast cells in early rheumatoid arthritis associate with disease severity and support B-cell autoantibody production. Annals of the Rheumatic Diseases 77(12), pp. 1773-1781. (10.1136/annrheumdis-2018-213418)
- Jones, S. A. and Jenkins, B. J. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Reviews Immunology 18, pp. 773-789. (10.1038/s41577-018-0066-7)
- Jones, G., Hill, D., Cardus Figueras, A. and Jones, S. 2018. IL-27 - a double agent in the IL-6 family. Clinical and Experimental Immunology 193(1), pp. 37-46. (10.1111/cei.13116)
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10(507), article number: eaan2787. (10.1126/scisignal.aan2787)
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Catar, R. et al. 2017. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. Journal of the American Society of Nephrology 28(4), pp. 1188-1199. (10.1681/ASN.2015101169)
- Dutzan, N. et al. 2017. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. Immunity 46(1), pp. 133-147. (10.1016/j.immuni.2016.12.010)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2(1) (10.12688/wellcomeopenres.10308.1)
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
- Jones, G., Hill, D. and Jones, S. 2016. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Frontiers in Immunology 7, pp. 1-13., article number: 401. (10.3389/fimmu.2016.00401)
- Liao, C. et al. 2016. IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation. European Journal of Immunology 46(9), pp. 2222-2232. (10.1002/eji.201646528)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Liu, X., Jones, G. W., Choy, E. H. and Jones, S. A. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
- Jones, G. W. and Jones, S. A. 2016. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147(2), pp. 141-151. (10.1111/imm.12554)
- Lacroix, M. et al. 2015. Novel insights into IL-6 cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. Journal of Biological Chemistry 290, pp. 26943-26953. (10.1074/jbc.M115.682138)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Beyer, C. et al. 2015. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases 74(6), pp. 1317-1324. (10.1136/annrheumdis-2013-204401)
- Hunter, C. A. and Jones, S. A. 2015. IL-6 as a keystone cytokine in health and disease. Nature Immunology 16(5), pp. 448-457. (10.1038/ni.3153)
- Rosser, E. C. et al. 2014. Regulatory B cells are induced by gut microbiota- driven interleukin-1β and interleukin-6 production. Nature Medicine 20, pp. 1334-1339. (10.1038/nm.3680)
- Garbers, C. et al. 2014. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochimica et Biophysica Acta - Molecular Basis of Disease 1842(9), pp. 1485-1494. (10.1016/j.bbadis.2014.05.018)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Pitzalis, C., Jones, G. W., Bombardieri, M. and Jones, S. A. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology 14(7), pp. 447-462. (10.1038/nri3700)
- Rosas, M. et al. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 344(6184), pp. 645-648. (10.1126/science.1251414)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Orr, S. J. et al. 2013. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. PLoS Pathogens 9(5), article number: e1003357. (10.1371/journal.ppat.1003357)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
- Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
- Chakraborty, M., McGreal, E. P., Davies, P. L., Nowell, M. A., Jones, S. A. and Kotecha, S. 2013. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. Neonatology 104(3), pp. 161-167. (10.1159/000351015)
- McDonald, J. U., Rosas, M., Brown, G. D., Jones, S. A. and Taylor, P. R. 2012. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS ONE 7(9), article number: e45781. (10.1371/journal.pone.0045781)
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- O'Connor, R. A., Floess, S., Huehn, J., Jones, S. A. and Anderton, S. M. 2012. Foxp3+Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production. European Journal of Immunology 42(5), pp. 1174-1179. (10.1002/eji.201142216)
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
- McDonald, J. U. et al. 2011. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. The FASEB Journal 25(6), pp. 1972-1982. (10.1096/fj.10-178517)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Rosas, M. et al. 2011. Hoxb8 conditionally immortalised macrophage lines model inflammatory monocytic cells with important similarity to dendritic cells. European Journal of Immunology 41(2), pp. 356-365. (10.1002/eji.201040962)
- Liddiard, K., Rosas, M., Davies, L. C., Jones, S. A. and Taylor, P. R. 2011. Macrophage heterogeneity and acute inflammation. European Journal of Immunology 41(9), pp. 2503-2508. (10.1002/eji.201141743)
- Davies, L. C., Rosas, M., Smith, P. J., Fraser, D. J., Jones, S. A. and Taylor, P. R. 2011. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. European Journal of Immunology 41(8), pp. 2155-2164. (10.1002/eji.201141817)
- Kennedy, C. L. et al. 2011. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. The Journal of Pathology 225(2), pp. 255-264. (10.1002/path.2933)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Jones, S. A., Scheller, J. and Rose-John, S. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121(9), pp. 3375-3383. (10.1172/JCI57158)
- McGreal, E. P., Chakraborty, M., Winter, V. T., Jones, S. A., Coalson, J. J. and Kotecha, S. 2011. Dynamic expression of IL-6 trans-signalling molecules in the lungs of preterm baboons undergoing mechanical ventilation. Neonatology 100(2), pp. 130-138. (10.1159/000322148)
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Leggate, M., Nowell, M. A., Jones, S. A. and Nimmo, M. N. 2010. The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress and Chaperones 15(6), pp. 827-833. (10.1007/s12192-010-0192-z)
- McGreal, E. P. et al. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease 1802(7-8), pp. 649-658. (10.1016/j.bbadis.2010.04.005)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
- Cash, H. et al. 2009. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. The Journal of Rheumatology 37(1), pp. 60-70. (10.3899/jrheum.090194)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Longhi, M. P. et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Dioszeghy, V. et al. 2008. 12/15-lipoxygenase regulates the inflammatory response to bacterial products in vivo. The Journal of Immunology 181(9), pp. 6514-6524.
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
- Dimitrov, S. et al. 2006. Sleep enhances IL-6 trans-signaling in humans. The FASEB Journal 20(12), pp. 2174-2176. (10.1096/fj.06-5754fje)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Peake, N. J. et al. 2006. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45(12), pp. 1485-1489. (10.1093/rheumatology/kel154)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
- McLoughlin, R. M. et al. 2004. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. The Journal of Immunology 172, pp. 5676-83.
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
- Robson, R. L., McLoughlin, R. M., Witowski, J., Loetscher, P., Wilkinson, T. S., Jones, S. A. and Topley, N. 2001. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo. The Journal of Immunology 167(2), pp. 1028-1038.
- Hurst, S. M. et al. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6), pp. 705-714. (10.1016/S1074-7613(01)00151-0)
Research
Cytokines regulate functions essential for normal physiology. However, their actions also promote immune-mediated diseases and associated co-morbidities. Jones has contributed discoveries that reveal how cells sense and interpret cytokine cues to instruct inflammation and the transition to chronic disease. This knowledge explains how cytokines that signal via the Jak-STAT pathway promote disease heterogeneity in rheumatoid arthritis and treatment failure in renal patients on peritoneal dialysis. His research has informed clinical studies (NCT03235752) and drug development in the pharmaceutical sector. Jones has three interlinked programs supported by funding from UKRI, charities and industry collaborations:
1. Identifying inflammatory checkpoints instructing the transition from innate to adaptive immunity– Effective communication between infiltrating leukocytes and the stromal tissue ensures an appropriate control of innate and adaptive immunity and resolving inflammation. Jones identified the regulatory properties of the soluble interleukin (IL)-6 receptor (sIL-6R) in this process and established the importance of IL-6 trans-signalling in bridging innate and adaptive immunity. He generated the first in vivo evidence of IL-6 trans-signalling involvement in disease, identified the first physiological regulator of sIL-6R production and established how sIL-6R shedding from infiltrating neutrophils synchronises IL-6 responses between stromal tissues and infiltrating leukocytes (Jones et al., J. Experimental Medicine 1999; Hurst et al., Immunity 2001; Nowell et al., J. Immunology 2003; McLoughlin et al., PNAS 2005). These publications altered our understanding of how IL-6 therapies (e.g., tocilizumab) work in pathology and established olamkicept as a first-in-class biological drug that inhibits IL-6 trans-signalling (Hurst et al., Immunity 2001; Nowell et al., J. Immunology 2003, 2009).
2. Defining mechanisms that promote tissue injury and disease progression– Jones identified how recurrent infections compromise the cytokine control of tissue homeostasis to drive fibrosis (Fielding et al., Immunity 2014). He showed that alterations to the local cytokine network following repeated bouts of inflammation distort acute resolving inflammation and promote tissue re-modelling through increased STAT1 transcription factor activity (Jones et al., J. Immunology 2010; Fielding et al., Immunity 2014). Relating these findings to rheumatoid arthritis, Jones showed that STAT1 shapes the transcriptional output of STAT3 in synovitis and contributes to disease heterogeneity (Nowell et al., J. Immunology 2009; Jones et al., Annals Rheumatic Disease 2013; Twohig et al., Nature Immunology 2019). His studies of IL-27 biology emphasise the importance of this mechanism in establishing lymphoid-rich synovitis, where ectopic lymphoid-like structures promote severe disease (Jones et al., J. Experimental Medicine 2015). In collaboration with GSK, Jones is exploring ways to combat lymphoid-driven pathology based on IL-27 biology.
3. Establishing how cells sense and interpret cytokine cues– Intracellular signalling pathways are finely tuned to change the interpretation of cytokine cues. Investigating cytokine responses in CD4+ T-cells, Jones identified that protein tyrosine phosphatases alter the transcriptional output of IL-6 in memory or activated subsets by inhibiting STAT1 activity (Twohig et al., Nature Immunology 2019). This rheostat mechanism explains how immune cells produce context-dependent cytokine responses and provides a hypothesis for increased disease susceptibility in patients with genetic polymorphisms in protein tyrosine phosphatases.
Biography
Education:
- Oct 1990- Dec 1993 Ph.D. (Biochemistry) Supervisors: Professor O.T.G. Jones (Department of Biochemistry, University of Bristol, Bristol, UK) and Dr N. Topley (Institute of Renal Medicine, University of Wales, College of Medicine, Cardiff, UK)
- Oct 1986- Jun 1990 B.Sc. Applied Biological Sciences (2.i Hons.) Bristol Polytechnic, Bristol, UK
Career Overview:
- 2023: Co-Director, Hodge Centre for Translational Neuroscience
- 2022: Co-Director, Systems Immunity Research Institute, The School of Medicine, Cardiff University
- 2017 - 2021: Dean of Research, The School of Medicine, Cardiff University
- 2015 - 2020: Theme Lead for Infection, Immunology & Inflammation, The College of Biomedical & Life Sciences, Cardiff University
- 2012 - 2017: Associate Director of Research, Division of Infection & Immunity, The School of Medicine, Cardiff University
- 2008 ‑ Professor of Inflammation Biology, School of Medicine, Cardiff University
- 2005 - 2008: Reader, School of Medicine, Cardiff University
- 2004 ‑ 2005: Reader, Cardiff School of Biosciences, Cardiff University
- 2003 - 2004: Senior Lecturer, Cardiff School of Biosciences, Cardiff University
- 1999 - 2003: Lecturer, Cardiff School of Biosciences, Cardiff University
- 1996 -1998: American Heart Association Fellow, Department of Cell Biology, University of Alabama at Birmingham, Alabama, USA (Director: Professor G.M. Fuller).
- 1994 - 1996: Swiss Foundation Research Fellow, Theodor Kocher Institute, University of Bern, Switzerland (Director: Professor M. Baggiolini).
Honours and awards
Member of Academia Europaea (Elected August 2021)
Fellow of The Learned Society of Wales (Elected May 2019)
Fellow of The Royal Society of Biology (Elected June 2015)
Health & Care Research Wales– Faculty Research Lead (Elected June 2014)
The 2004 Bolzmann Award– Presented by the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR) for contributions to cytokine biology.
Professional memberships
Grant Panel Membership:
Medical Research Council (UKRI)
Infection & Immunity Board (2020-25)
COVID-19 Agile Committee (2020-21)
Versus Arthritis.
Research Sub-Committee (2011-16; Vice Chair 2015, 2016)
Programme Grant Outline Committee (2015, 2016)
USER Committee (Scientific Advisor, Lay Panel; 2015, 2016)
Versus Arthritis/Cancer Research UK Partnership Group (2018)
Disease Sub-Committee– (Vice Chair 2017-20)
Health & Care Research Wales.
Grants Committee Member (2012)
Research for Patient & Public Benefit (Deputy Chair; 2013-18)
Health Fellowships Committee (2014)
Health Research Board Ireland.
Joint Medical Research Charities Committee (2016, 2018)
Investigator-Led Projects (Chair 2019, 2022)
Trials Methodology Research Network Review Panel (Chair 2021)
Royal Irish Academy.
Early Entry Grant Panel (2008)
Research Advisory Groups:
Government
Welsh Higher Education Brussels (WHEB) Board– Development of European Funding for Welsh Universities
Cardiff Ambassador– Supporting commercial activities in Cardiff (e.g., industry links, conferences)
Pharmaceutical companies
Roche/Chugai– Panel Member for Actemra (tocilizumab) Translational Research Board (2008-2012)
Genentech– Translational Immunology Summit Advisory Board
Eleven Biotherapeutics– Clinical application of biologic drugs EBI-029 and EBI-031
EUSA Pharma– Use of Sirukumab in the treatment of cancer and associated co-morbidity.
Janssen (Johnson & Johnson & GSK)– The clinical application of Sirukumab.
NovImmune AG– Development of biological drugs NI-0101 and NI-1201
Ferring Pharmaceuticals– Clinical development of Olamkicept.
Regeneron/Sanofi– The clinical application of Sarilumab
Glaxo-Smith-Kline– Development of biological drugs against oncostatin-M and IL-27
Charity Sector
Versus Arthritis Senior Stakeholder Group–
Versus Arthritis Centre Strategy Review Committee (2019-2020)
Academy of Medical Sciences– Invited to research steering groups (‘Advancing research to tackle multimorbidity– the UK perspective’; ‘Multimorbidity: a priority for global health research’– 2018, 2019).
Editorial Board Membership:
Journal of Biological Chemistry (Editorial Board Member– Immunology) (2015-2021)
Frontiers in Immunology (Pro-inflammatory Cytokines)
Function (linked to the American Society of Physiology)
Society Memberships:
The Biochemical Society (Theme Panel V Member; 2008-2013)
International Cytokine and Interferon Society (Member of the Meeting Committee; 2017-2024, Member of the Development Committee; 2018-2022)
The Learned Society of Wales
Academia Europaea
Royal Society of Biology
Academic positions
- Apr 2021- to present. Co-Director, Systems Immunity Research Institute, Cardiff University, UK
- Apr 2017- Mar 2021. Dean of Research, The School of Medicine, Cardiff University
- Mar 2015‑ Sept 2020. College Theme Lead for Infection, Immunology & Inflammation, College of Biomedical & Life Sciences, Cardiff University.
- May 2015- Mar 2017. Deputy Director, Division of Infection & Immunity, The School of Medicine
- Jun 2012-May 2015 Associate Director of Research for Infection & Immunity Institute for Infection & Immunity, The School of Medicine
- Jan 2005‑ Jul 2008 Reader School of Medicine, Cardiff University, UK
- Jan 2004‑ Dec 2004 Reader Cardiff School of Biosciences, Cardiff University, UK
- Sept 2003- Jan 2004 Senior Lecturer Cardiff School of Biosciences, Cardiff University, UK
- Jan 1999- Sept 2003 Lecturer Cardiff School of Biosciences, Cardiff University, UK
- Jul 1996- Dec 1998 American Heart Association Research Fellow Dept. of Cell Biology, University of Alabama at Birmingham
- Jan 1994- Jun 1996 Swiss Foundation Research Fellow Theodor Kocher Institute, University of Bern, Switzerland
Speaking engagements
Examples of invited conference lectures:
- 3rd Int. Symposium of Collaborative Research Centre-877 (2022)– Plenary Speaker, Kiel, Germany
- EMBO Lecture Course (2022)– Faculty member, Invited Plenary Speaker, Spetses, Greece
- International Cytokine & Interferon Society (2019)– Invited plenary speaker, Vienna, Austria
- 16th Scleroderma Research Workshop (2019)– Invited plenary speaker, Cambridge, UK
- 37th Congress of the Spanish Society of Pharmacology (Partnered with the British Society for Pharmacology)– Invited plenary speaker, Barcelona, Spain (2017)
- British Society for Rheumatology– Invited plenary speaker (Session Sponsored by the British Society of Immunology), Birmingham, UK (2017)
- Meet the Mesothelium (Sponsored: Kidney Research UK) – Invited speaker, Manchester, UK (2016)
- International Congress of Immunology (2016)– Invited speaker, Melbourne, Australia
- Keystone - Cytokine Jak-STAT signalling in immune disease (2016)– Invited speaker, Colorado, USA
- 12th European peritoneal dialysis meeting (2015)– Invited plenary speaker, Krakow, Poland
- 14th Scleroderma Research Workshop (2015)– Invited plenary speaker, Cambridge, UK
- International Cytokine & Interferon Society (2014)– Invited plenary speaker, Melbourne, Australia
- British Society for Rheumatology (2014)– Invited plenary speaker, Liverpool, UK
- American College of Rheumatology (2013)– Keynote plenary speaker, San Diego, USA
- Keystone Conference– Biology of Cytokines & Th17 Cells in Health & Disease (2012), Colorado, USA
- University of Pennsylvania, USA, Department of Veterinary Pathology– Invited Speaker (2011)
- University of Alabama at Birmingham, USA, Department of Pathology– Invited Speaker (2011)
- German Society for Biochemistry & Molecular Biology (2007)– Plenary speaker, Hamburg, Germany
- Australian Society for Medical Research (2006)– Invited plenary speaker, Melbourne, Australia
Examples of contributions to medical education programmes:
- Immune Mediated and Inflammatory Disease Summit (with Janssen Pharmaceuticals)– Royal College of Physicians, London (2017)
- Midlands Clinical Rheumatology Meeting– Keynote Lecture: ‘The biology behind IL-6 therapy’ (2017)
- CESAS Medical– ‘Considering Interleukin-6’ (one of five invited speakers)– London, UK (2017) (see: https://considerations.bmj.com/content/2/1)
- Peninsula & Severn Clinical Rheumatology Meeting– Invited Lecture – Taunton, Somerset, UK (2016)
- European League against rheumatism: Roche sponsored satellite meeting (2012)– Berlin, Germany.
- American College of Rheumatology: Roche sponsored satellite meeting (2011)– Chicago, USA
Organisation of International Scientific Conferences:
- International Cytokine & Interferon Society Annual Conference (2026)– Chair of Organising committee for the forthcoming Cytokines2026, Cardiff, Wales, UK
- International Cytokine & Interferon Society Annual Conference (2021)– Chair of Organising committee for Cytokines2021, Cardiff City Hall, Cardiff, Wales, UK
- International Cytokine & Interferon Society Conference (Oct 2014)– Member of the International Organising Committee for Cytokine 2014, Melbourne, Australia
- Biochemical Society– Member; Theme Panel-V (2008-12)– Review of meetings in Signal transduction.
Committees and reviewing
Current management and leadership responsibilities-
- Dean of Research for The School of Medicine - since May 2017
- School Board Committee - since May 2017
- School of Medicine, Executive Committee - since May 2017
- Chair of The REF Planning Committee, The School of Medicine - since July 2017
- Theme Lead for Infection, Immunity & Inflammation, College of Biomedical & Life Sciences (CBLS) - since 2015
- College Research Board Member, CBLS - since 2015
- Wellcome Trust ISSF Board member
- Lead for Equipment & Infrastructure in CBLS - Since 2016
- Research Management Group Committee, School of Medicine - Since 2013
- Division of Infection & Immunity Steering Committee - 2010-2017
- Research Lead for Inflammation Research, Division of Infection & Immunity, The School of Medicine - 2012-2017
- Systems Immunity URI Executive Committee- Since 2015
- Research Lead for Inflammation Research, Systems Immunity URI - 2015-2017
- Member of the College of Experts Peer Review Panel - Since 2012
- Internal Review Panel member for Wellcome Trust ISSF Awards (Chair of Mobility Award Panel, Equipment Assessment Panel member)
- Review panel member of the COFUND/Ser Cymru, and Capital Medical University (China) Fellowship Schemes
- Executive Committee for the Cardiff Regional Experimental Arthritis Treatment Centre (Basic Science Lead) - Since 2013
- Governance Committee for Human Tissue Bank (Kidney) - Since 2014
- Management Committee, Arthritis Research UK Centre of Excellence - Since 2015
- Scientific Misconduct Review – member of a panel that conducted an internal allegations review process (2016).
- Member of the Hodge Foundation Executive Committee – linking immunology & Neuroscience
Contact Details
JonesSA@cardiff.ac.uk
+44 29206 87325
Sir Geraint Evans Cardiovascular Research Building, Floor Second Floor, Room 2F/02, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
+44 29206 87325
Sir Geraint Evans Cardiovascular Research Building, Floor Second Floor, Room 2F/02, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
